or Try an Advanced Search...

    Technical Analysis for RZLT - Rezolute, Inc.

    Grade Last Price % Change Price Change
    B 4.03 -2.89% -0.12
    RZLT closed down 2.89 percent on Friday, May 31, 2024, on 45 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical RZLT trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    New 52 Week Closing High Bullish -2.89%
    Calm After Storm Range Contraction -2.89%
    Doji - Bearish? Reversal -2.89%
    New 52 Week High Strength -2.89%
    Older End-of-Day Signals for RZLT ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 2 days ago
    Possible Inside Day 2 days ago
    60 Minute Opening Range Breakdown 2 days ago
    Down 3% 2 days ago
    Down 2 % 2 days ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    RZLT Chart by TradingView
    Basic chart:

    Profile

    Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. Its products include RZ358, a human monoclonal antibody that is in Phase II clinical trial for the treatment of congenital hyperinsulinism, a devastating ultra-orphan pediatric disease; and RZ402, a plasma kallikrein inhibitor, which is in late stage preclinical program for the treatment of diabetic macular edema. It also develops AB101, a human recombinant insulin, which is in Phase I clinical trial for the treatment of patients with type 1 and type 2 diabetes mellitus. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Life Sciences Diabetes Cancer Treatment Monoclonal Antibody Insulin Metabolic Disease Specialty Drugs Diabetes Mellitus Diabetic Retinopathy Macular Edema Diabetic Macular Edema Kallikrein Plasma Kallikrein

    Is RZLT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 30 Rezolute to Participate in the Jefferies Global Healthcare Conference
    May 21 Rezolute stock rockets 50% on Phase 2 results for eye drug RZ402
    May 21 Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
    May 16 Rezolute reports Q3 results
    May 15 Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
    May 10 Rezolute, Inc. (NASDAQ:RZLT) has caught the attention of institutional investors who hold a sizeable 47% stake
    Apr 23 Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
    Apr 1 CommScope Holding And 2 Other Stocks Under $3 Insiders Are Buying
    Mar 27 Rezolute Reaches US$75m Market Cap Benefiting Insider Stock Buying
    Mar 20 $17M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
    See more RZLT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.4
    52 Week Low 0.72
    Average Volume 586,171
    200-Day Moving Average 1.60
    50-Day Moving Average 2.84
    20-Day Moving Average 3.14
    10-Day Moving Average 3.39
    Average True Range 0.39
    RSI (14) 69.14
    ADX 42.56
    +DI 37.85
    -DI 6.83
    Chandelier Exit (Long, 3 ATRs) 3.23
    Chandelier Exit (Short, 3 ATRs) 3.65
    Upper Bollinger Bands 4.13
    Lower Bollinger Band 2.15
    Percent B (%b) 0.95
    BandWidth 63.05
    MACD Line 0.31
    MACD Signal Line 0.18
    MACD Histogram 0.133
    Fundamentals Value
    Market Cap 159.69 Million
    Num Shares 39.6 Million
    EPS -1.10
    Price-to-Earnings (P/E) Ratio -3.66
    Price-to-Sales 0.00
    Price-to-Book 0.38
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.36
    Resistance 3 (R3) 4.37 4.27 4.31
    Resistance 2 (R2) 4.27 4.19 4.27 4.29
    Resistance 1 (R1) 4.15 4.13 4.10 4.14 4.27
    Pivot Point 4.05 4.05 4.03 4.05 4.05
    Support 1 (S1) 3.93 3.97 3.88 3.92 3.79
    Support 2 (S2) 3.83 3.91 3.83 3.77
    Support 3 (S3) 3.71 3.83 3.76
    Support 4 (S4) 3.70